# US 2003/0212073 A1 · Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0212073 A1
- Document ID: US20030212073A1
- Status: Published application
- Kind: A1
- Application number: 10/419,682
- Filed: 2003-04-21
- Published: 2003-11-13
- Earliest claimed: 2002-04-19
- Assignees: Cellular Genomics, Inc.
- Inventors: Kevin S. Currie; Robert W. DeSimone; Douglas A. Pippin; James W. Darrow; Scott A. Mitchell
- Web page: https://patentgrep.com/patent/US20030212073A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/10: of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 7/06: Antianaemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/08: Bronchodilators
- A61P 13/08: of the prostate
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A novel composition comprises a compound of Formula 1 1 the pharmaceutically acceptable salts, hydrates, solvates, crystal forms, diastereomers, prodrugs, or mixtures thereof. The composition is of particular utility in the treatment of kinase-implicated disorders.

## Claims

### Claim 1

A compound having of Formula 1
11
a pharmaceutically acceptable salt, hydrates, solvate, crystal form, diastereomer, prodrug, or mixture thereof, wherein
R1 is hydrogen; cyclo-(C3-C6 alkyl)-methyl; straight or branched chain C1-C7 alkyl, in which the branched alkyl chains may form a 3 to 7 member heteroalkyl or alkyl ring; sulfonamide; C1-C6 alkoxy; (C1-C6)-alkyl-oxy-(C1-C6)alkoxy; mono- or di(C1-C6 alkyl)amino; mono- or di(C1-C6 alkyl)amino(C1-C6 alkyl); or phenyl or heteroaryl ring which may be unsubstituted, or mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, sulfonamide, halogen, C1-C6 alkyl, C1-C6 perfluoroalkyl, C1-C6 perfluoroalkoxy, C1-C6 alkoxy, mono- or di(C1-C6 alkyl)amino, or mono- or di(C1-C6 alkyl)amino(C1-C6 alkyl); and,
R2 is straight or branched chain C1-C7 alkyl, in which the branched alkyl chains may form a 3-7 member heteroalkyl or alkyl ring; cyclo-(C3-C6 alkyl)-methyl; C1-C6 alkoxy, except when Z2 is phenylene and A is 0 and R1 is straight or branched chain C1-C7 alkyl (but not cycloalkyl), phenyl, or phenyl substituted with hydroxy, nitro, cyano, amino, C1-C6 alkoxy, or halogen, or when A is 1 and Z1 is —C(R4)(R5)— wherein m is 1, 2, or 3 and R1 is straight or branched chain C1-C7 alkyl (but not cycloalkyl), phenyl, or phenyl substituted with hydroxy, nitro, cyano, amino, C1-C6 alkoxy, or halogen, or when Z2 is phenylene, A is 1, Z, is —C(R4)(R5)— wherein m is 1, 2, or 3, and R1 is straight or branched chain C1-C7 alkyl (but not cycloalkyl), phenyl, or phenyl substituted with hydroxy, nitro, cyano, amino, C1-C6 alkoxy, or halogen, or when Z2 is —C(R7)(R8)— wherein n is 1, 2, or 3, each occurrence of R7 and R8 is independently straight or branched chain C1-C6 alkyl or halogen and R2 is C1-C6 alkoxy or phenyl substituted with nitro; (C1-C6)-alkyl-oxy-(C1-C6)alkoxy; or phenyl or heteroaryl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro (except when Z2 is phenylene and A is 0 and R1 is straight or branched chain C1-C7 alkyl (but not cycloalkyl), phenyl, or phenyl substituted with hydroxy, nitro, cyano, amino, C1-C6 alkoxy, or halogen, or when A is 1 and Z, is —C(R4)(R5)— wherein m is 1, 2, or 3, and R1 is straight or branched chain C1-C7 alkyl (but not cycloalkyl), phenyl, or phenyl substituted with hydroxy, nitro, cyano, amino, C1-C6 alkoxy, or halogen, or when Z2 is phenylene and A is 1 and Z, is —C(R4)(R5)— wherein m is 1, 2, or 3, and R1 is straight or branched chain C1-C7 alkyl (but not cycloalkyl), phenyl, or phenyl substituted with hydroxy, nitro, cyano, amino, C1-C6 alkoxy, or halogen, or when Z2 is —C(R7)(R8)— wherein n is 1, 2, or 3, each occurrence of R7 and R8 is independently straight or branched chain C1-C6 alkyl or halogen and R2 is C1-C6 alkoxy or phenyl substituted with nitro), cyano, amino, halogen, C1-C6 alkyl, C1-C6 perfluoroalkyl, C1-C6 perfluoroalkoxy, C1-C6 alkoxy, (C1-C6)-alkyl-oxy-(C1-C6)alkoxy, mono- or di(C1-C6 alkyl)amino, or amino(C1-C6 alkyl); phenyoxy phenyl where each phenyl may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide, C1-C6 alkyl, C1-C6 perfluoroalkyl, C1-C6 perfluoroalkoxy, C1-C6 alkoxy, (C1-C6)-alkyl-oxy-(C1-C6)alkoxy, mono- or di(C1-C6 alkyl)amino, or amino(C1-C6 alkyl); phenyl or heteroaryl piperazine where the phenyl or heteroaryl ring may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide, C1-C6 alkyl, C1-C6 perfluoroalkyl, C1-C6 perfluoroalkoxy, C1-C6 alkoxy, (C1-C6)-alkyl-oxy-(C1-C6)alkoxy, mono- or di(C1-C6 alkyl)amino, or mono- or di(C1-C6 alkyl)amino(C1-C6 alkyl);
R3 is hydrogen; straight or branched chain C1-C7 alkyl, in which the branched alkyl chains may form a 3-7 member heteroalkyl or alkyl ring;
Z1 is
12
wherein
A is 0 or 1;
each occurrence of R4 and R5 is independently hydrogen, straight or branched chain C1-C6 alkyl, sulfonamide, or halogen;
m is 0, 1, or 2; and
R6 is hydrogen; straight or branched chain C1-C6 alkyl; phenyl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, C1-C6 alkyl, C1-C6 perfluoroalkyl, C1-C6 perfluoroalkoxy, C1-C6 alkoxy, (C1-C6)-alkyl-oxy-(C1-C6)alkoxy, mono- or di(C1-C6 alkyl)amino, or amino(C1-C6 alkyl); or heteroaryl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, C1-C6 alkyl, C1-C6 perfluoroalkyl, C1-C6 perfluoroalkoxy, C1-C6 alkoxy, (C1-C6)-alkyl-oxy-(C1-C6)alkoxy, mono- or di(C1-C6 alkyl)amino, or amino(C1-C6 alkyl); and
Z2 is a divalent linking group selected from para-phenylene, meta-phenylene, ortho-phenylene, naphthylene,
13
wherein
each occurrence of R7 and R8 is independently straight or branched chain C1-C6 alkyl, sulfonamide, or halogen;
n is 1, 2, or 3; and
R9-R12 are each independently hydrogen; straight or branched chain C1-C6 alkyl; phenyl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, C1-C6 alkyl, C1-C6 perfluoroalkyl, C1-C6 perfluoroalkoxy, C1-C6 alkoxy, (C1-C6)-alkyl-oxy-(C1-C6)alkoxy, mono- of di(C1-C6 alkyl)amino, or amino(C1-C6 alkyl); or heteroaryl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 perfluoroalkyl, C1-C6 perfluoroalkoxy, (C1-C6)-alkyl-oxy-(Ci -C6)alkoxy, mono- or di(C1-C6 alkyl)amino, or amino(C1-C6 alkyl).

### Claim 2

A compound having Formula 2
14
a pharmaceutically acceptable salt, hydrates, solvate, crystal form, diastereomer, prodrug, or mixture thereof, wherein
R1 is hydrogen; cyclo-(C3-C6 alkyl)-methyl; straight or branched chain C1-C7 alkyl, in which the branched alkyl chains are allowed to also form a 3-7 member heteroalkyl or alkyl ring; sulfonamide; C1-C6 alkoxy; (C1-C6)-alkyl-oxy-(C1-C6)alkoxy; mono- or di(C1-C6 alkyl)amino, or mono- or di(C1-C6 alkyl)amino(C1-C6 alkyl); or phenyl or heteroaryl ring which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, sulfonamide, halogen, C1-C6 alkyl, C1-C6 perfluoroalkyl, C1-C6 perfluoroalkoxy, C1-C6 alkoxy, mono- or di(C1-C6 alkyl)amino, or mono- or di(C1-C6 alkyl)amino(C1-C6 alkyl);
R2 in Formula 2 is straight or branched chain C1-C7 alkyl, in which the branched alkyl chains are allowed to also form a 3-7 member heteroalkyl or alkyl ring; cyclo-(C3-C6 alkyl)-methyl; C1-C6 alkoxy except when A is 0 and R1 is straight or branched chain C1-C7 alkyl (but not cycloalkyl), phenyl, or phenyl substituted with hydroxy, nitro, cyano, amino, C1-C6 alkoxy, or halogen, or when A is 1 and Z, is —C(R4)(R5)— wherein m is 1, 2, or 3 and R1 is straight or branched chain C1-C7 alkyl (but not cycloalkyl), phenyl, or phenyl substituted with hydroxy, nitro, cyano, amino, C1-C6 alkoxy, or halogen; (C1-C6)-alkyl-oxy-(C1-C6)alkoxy; phenyl or heteroaryl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro (except when A is 0 and R1 is straight or branched chain C1-C7 alkyl (but not cycloalkyl), phenyl, or phenyl substituted with hydroxy, nitro, cyano, amino, C1-C6 alkoxy, or halogen, or when A is 1 and Z, is —C(R4)(R5)— wherein m is 1, 2, or 3, and R1 is straight or branched chain C1-C7 alkyl (but not cycloalkyl), phenyl, or phenyl substituted with hydroxy, nitro, cyano, amino, C1-C6 alkoxy, or halogen), cyano, amino, halogen, C1-C6 alkyl, C1-C6 perfluoroalkyl, C1-C6 perfluoroalkoxy, C1-C6 alkoxy, (C1-C6)-alkyl- oxy-(C1-C6)alkoxy, mono- or di(C1-C6 alkyl)amino, amino(C1-C6 alkyl); phenyoxy phenyl where each phenyl may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide, C1-C6 alkyl, C1-C6 perfluoroalkyl, C1-C6 perfluoroalkoxy, C1-C6 alkoxy, (C1-C6)-alkyl-oxy-(C1-C6)alkoxy, mono- or di(C1-C6 alkyl)amino, or amino(C1-C6 alkyl); or phenyl or heteroaryl piperazine where the phenyl or heteroaryl ring may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide, C1-C6 alkyl, C1-C6 perfluoroalkyl, CI -C6 perfluoroalkoxy, C1-C6 alkoxy, (C1-C6)-alkyl-oxy-(Ci -C6)alkoxy, mono- or di(C1-C6 alkyl)amino, or mono- or di(C1-C6 alkyl)amino(C1-C6 alkyl);
R3 in Formula 2 may be hydrogen; straight or branched chain C1-C7 alkyl, in which the branched alkyl chains can also form a 3-7 member heteroalkyl or alkyl ring;
A in Formula 2 is 0 or 1; and
Z, in Formula 2 is
15
wherein
each occurrence of R4and R5 is independently hydrogen, straight or branched chain C1-C6 alkyl, sulfonamide, or halogen;
m is 1, 2, or 3; and
R6 is hydrogen; straight or branched chain C1-C6 alkyl; phenyl, which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, C1-C6 alkyl, C1-C6 perfluoroalkyl, C1-C6 perfluoroalkoxy, C1-C6 alkoxy, (C1-C6)-alkyl-oxy-(C1-C6)alkoxy, mono- or di(C1-C6 alkyl)amino, or amino(C1-C6 alkyl); or heteroaryl, which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, C1-C6 alky, C1-C6 perfluoroalkyl, C1-C6 perfluoroalkoxy, C1-C6 alkoxy, (C1-C6)-alkyl-oxy-(C1-C6)alkoxy, mono- or di(C1-C6 alkyl)amino, or amino(C1-C6 alkyl).

### Claim 3

A compound having Formula 3:
16
a pharmaceutically acceptable salt, hydrates, solvate, crystal form, diastereomer, prodrug, or mixture thereof, wherein
a is 0, 1, 2 or 3;
R14 is hydrogen; cyclo-(C3-C6 alkyl)-methyl; straight or branched chain C1-C6 alkyl, in which the branched alkyl chains may form a 3-7 member heteroalkyl or alkyl ring; sulfonamide; C1-C6 alkoxy; (C1-C6)-alkyl-oxy-(C1-C6)alkoxy; mono- or di(C1-C6 alkyl)amino, mono- or di(C1-C6 alkyl)amino(C1-C6 alkyl); or phenyl or heteroaryl ring, which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, sulfonamide, halogen, C1-C6 alkyl, Ci -C6 perfluoroalkyl, C1-C6 perfluoroalkoxy, C1-C6 alkoxy, mono- or di(C1-C6 alkyl)amino, or mono- or di(C1-C6 alkyl)amino(C1-C6 alkyl);
R2 in Formula 3 is straight or branched chain C1-C6 alkyl, in which the branched alkyl chains may form a 3-7 member heteroalkyl or alkyl ring; cyclo-(C3-C6 alkyl)-methyl; C1-C6 alkoxy except where R1 is hydrogen, C1-C6 alkoxy, or phenyl substituted with nitro; (C1-C6)-alkyl-oxy-(C1-C6)alkoxy; phenyl or heteroaryl, which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, C1-C6 alkyl, C1-C6 perfluoroalkyl, C1-C6 perfluoroalkoxy, C1-C6 alkoxy, (C1-C6)-alkyl-oxy-(C1-C6)alkoxy, mono- or di(C1-C6 alkyl)amino, or amino(C1-C6 alkyl); phenyoxy phenyl, in which each phenyl may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro (except where R1 is hydrogen, C1-C6 alkoxy, or phenyl substituted with nitro), cyano, amino, halogen, sulfonamide, C1-C6 alkyl, C1-C6 perfluoroalkyl, C1-C6 perfluoroalkoxy, C1-C6 alkoxy, (C1-C6)-alkyl-oxy-(C1-C6)alkoxy, mono- or di(C1-C6 alkyl)amino, or amino(C1-C6 alkyl); or phenyl or heteroaryl piperazine, in which the phenyl or heteroaryl ring may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide, C1-C6 alkyl, C1-C6 perfluoroalkyl, C1-C6 perfluoroalkoxy, C1-C6 alkoxy, (C1-C6)-alkyl-oxy-(C1-C6)alkoxy, mono- or di(C1-C6 alkyl)amino, or mono- or di(C1-C6 alkyl)amino(C1-C6 alkyl); and
R3 is hydrogen; straight or branched chain C1-C6 alkyl, in which the branched alkyl chains may form a 3-7 member heteroalkyl or alkyl ring.

### Claim 4 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(4-chloro-phenyl)-3-[3-(8-methyl amino-imidazo [1,2-a]pyrazin-6-yl)-phenyl]-urea.

### Claim 5 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(4-chloro-phenyl)-3-[3-(8-phenylamino-imidazo[1,2-a]pyrazin-6-yl)-phenyl]-urea.

### Claim 6 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(4-chloro-phenyl)-3-{3-[8-(4-chlorophenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea.

### Claim 7 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(4-chloro-phenyl)-3-{3-[8-(3-chlorophenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea.

### Claim 8 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(4-chloro-phenyl)-3-{3-[8-(2-chlorophenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea.

### Claim 9 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(4-chloro-phenyl)-3-{3-[8-(pyridin-3-ylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea.

### Claim 10 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-{3-[8-(4-chlorobenzylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-(4-chloro-phenyl)-urea.

### Claim 11 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-{3-[8-(3-chlorobenzylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-(4-chloro-phenyl)-urea.

### Claim 12 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-{4-[8-(4-chlorobenzylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-(4-chloro-phenyl)-urea.

### Claim 13 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-{4-[8-(3-chlorobenzylamino)-imidazo [1,2-a]pyrazin-6-yl]-phenyl }-3-(4-chloro-phenyl)-urea.

### Claim 14 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 4-(6-{3-[3-(4-chlorophenyl)-ureido]-phenyl}-imidazo[1,2-a]pyrazin-8-ylamino)-benzoic acid ethyl ester.

### Claim 15 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is cyclopropylmethyl-[6-(4-phenoxyphenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine.

### Claim 16 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is (2-methoxybenzyl)-[6-(4-phenoxyphenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine.

### Claim 17 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is benzo[1,3]dioxol-5-ylmethyl-[6-(4-phenoxyphenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine.

### Claim 18 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is [6-(4-(chloromethyl)phenyl)-imidazo[1,2-a]pyrazin-8-yl]-(2-methoxy-benzyl)-amine.

### Claim 19 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-{4-[8-(2-methoxybenzylamino)-imidazo [1,2-a]pyrazin-6-yl]-phenyl }-3-phenyl-urea.

### Claim 20 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is (2-methoxy-benzyl)-{6-[4-(4-methoxybenzylamino)-phenyl]-imidazo[1,2-a]pyrazin-8-yl}-amine.

### Claim 21 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is (2-methoxy-benzyl)-{6-[3-(4-methoxybenzylamino)-phenyl]-imidazo[1,2-a]pyrazin-8-yl}-amine.

### Claim 22 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-{3-[8-(2-methoxybenzylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-phenyl-urea.

### Claim 23 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(2-chloro-phenyl)-3-{4-[8-(2-methoxybenzylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea.

### Claim 24 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-{4-[8-(2-methoxybenzylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-(2-methoxy-phenyl)-urea.

### Claim 25 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-{4-[8-(2-ethoxybenzylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-(3-methoxy-phenyl)-urea.

### Claim 26

A compound according to claim embodiment 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compounds is 4-{6-[4-(piperidine-1-carbonyl)-phenyl]-imidazo[1,2-a]pyrazin-8-ylamino}-benzoic acid ethyl ester.

### Claim 27 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 4-(6-{3-[3-(4-chlorophenyl)-ureido]-phenyl}-imidazo[1,2-a]pyrazin-8-ylamino)-benzoic acid ethyl ester.

### Claim 28 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 4-(6-{3-[3-(2-methylsulfanyl-phenyl)-ureido]-phenyl}-imidazo[1,2-a]pyrazin-8-ylamino)-benzoic acid ethyl ester.

### Claim 29 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is {4-[8-(4-chlorophenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-piperidin-1-yl-methanone.

### Claim 30 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is {4-[8-(2-chlorophenylamino)-imidazo [1,2-a]pyrazin-6-yl]-phenyl }-piperidin-1-yl-methanone.

### Claim 31 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 3-methoxy-N-{4-[8-(2-methoxybenzylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-benzamide.

### Claim 32 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-chloro-4-fluorophenyl)-3-[3-(8-phenylamino-imidazo[1,2-a]pyrazin-6-yl)-phenyl]-urea.

### Claim 33 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(4-chlorophenyl)-3-[3-(8-phenylamino-imidazo[1,2-a]pyrazin-6-yl)-phenyl]-urea.

### Claim 34 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-[3-(8-phenylamino-imidazo[1,2-a]pyrazin-6-yl)-phenyl]-3-(3-trifluoromethyl-phenyl)-urea.

### Claim 35 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(2-chloro-5-trifluoromethyl-phenyl)-3-[3-(8-phenylamino-imidazo[1,2-a]pyrazin-6-yl)-phenyl]-urea.

### Claim 36 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(4-chlorophenyl)-3-{3-[8-(4-chlorophenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea.

### Claim 37 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-{3-[8-(4-chloro-phenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-(3-trifluoromethylphenyl)-urea.

### Claim 38 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-chloro-4-fluorophenyl)-3-{3-[8-(3-chlorophenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea.

### Claim 39 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(4-chlorophenyl)-3-{3-[8-(3-chlorophenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea.

### Claim 40 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-{3-[8-(3-chlorophenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-(3-trifluoromethylphenyl)-urea.

### Claim 41 (depends on 1)

A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-chloro-4-fluorophenyl)-3-{3-[8-(2-chlorophenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

A compound, pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug as in claims 1 to 41, wherein in an in vitro assay of kinase modulation, the compound exhibits a IC50 value less than or equal to 25 micromolar.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

A compound, pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug as in claims 1 to 41, wherein in an in vitro assay of modulation of soft agar growth, the compound exhibits a IC50 value less than or equal to 25 micromolar.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

A compound, pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug as in claims 1 to 41, wherein in an in vitro assay of modulation of soft agar growth, wherein the cells are HCT-15, MiaPaca-2, MCF-7, OVCAR-4, or A549 cells, the compound exhibits a IC50 value less than or equal to 25 micromolar.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

A pharmaceutical composition comprising
a compound, pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug as in claims 1 to 41; and
at least one pharmaceutically acceptable carrier or excipient.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

A method of treating a kinase-implicated condition in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound, pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug claims 1 to 41.

### Claim 47 (depends on 46)

The method of claim 46, wherein the mammal is a human.

### Claim 48 (depends on 46)

The method of claim 46, wherein the mammal is a dog or cat.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

A method of treating cancer, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound, pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug of claims 1 to 41.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

A method of treating cancer, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound, pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug of claims 1 to 41 and a therapeutically effective amount of an antitumor therapeutic.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 50)

The method of claim 50, wherein treatment with the antitumor therapeutic follows treatment with the compound, pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug of claims 1 to 41.

### Claim 52 (depends on 50)

The method of claim 50, wherein the antitumor therapeutic is a chemotherapeutic agent.

### Claim 53 (depends on 52)

The method of claim 52, wherein the chemotherapeutic agent is mitomycin C, carboplatin, taxol, cisplatin, paclitaxel, etoposide, doxorubicin, or a combination comprising at least one of the foregoing chemotherapeutic agents.

### Claim 54 (depends on 50)

The method of claim 50, wherein the antitumor therapeutic is a radiotherapeutic agent.

### Claim 55 (depends on 50)

The method of claim 50, wherein the mammal is a human.

### Claim 56 (depends on 50)

The method of claim 50, wherein the mammal is a dog or cat.

### Claim 57 (depends on 1)

A method for identifying a kinase, comprising contacting an organism, cell, or preparation comprising the kinase with a compound or salt according to claim 1, and detecting modulation of an activity of the kinase.
